Skip to main content

LCD L39262: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

LCD L39262, MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia, is the Local Coverage Determination that Noridian Healthcare Solutions, LLC applies to claims from 13 states plus 3 territories (AK, AS, AZ, CA, GU, HI, ID, MP and others), effective 2026-01-22 and first in force 2023-05-28. The policy text runs 292 words. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 0 covered ICD-10-CM codes: the same total as L39256 (Palmetto GBA, 0 codes, revised 2025-03-13) and the same total as L39276 (CGS Administrators, LLC, 0 codes, revised 2026-02-19).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Noridian Healthcare Solutions, LLC
States and territories
16
AK AS AZ CA CNMI GU HI ID MT ND NV OR SD UT WA WY
Revision effective
2026-01-22
Original effective
2023-05-28
Policy text
292 words
Covered ICD-10 codes (articles)
0

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39262
ContractContractorTypeStates
03201Noridian Healthcare Solutions, LLCA and B MACMT
03301Noridian Healthcare Solutions, LLCA and B MACND
03401Noridian Healthcare Solutions, LLCA and B MACSD
03501Noridian Healthcare Solutions, LLCA and B MACUT
03601Noridian Healthcare Solutions, LLCA and B MACWY
03102Noridian Healthcare Solutions, LLCA and B MACAZ
03202Noridian Healthcare Solutions, LLCA and B MACMT
03302Noridian Healthcare Solutions, LLCA and B MACND
03502Noridian Healthcare Solutions, LLCA and B MACUT
03602Noridian Healthcare Solutions, LLCA and B MACWY
03402Noridian Healthcare Solutions, LLCA and B MACSD
03101Noridian Healthcare Solutions, LLCA and B MACAZ
02201Noridian Healthcare Solutions, LLCA and B MACID
02101Noridian Healthcare Solutions, LLCA and B MACAK
02301Noridian Healthcare Solutions, LLCA and B MACOR
02401Noridian Healthcare Solutions, LLCA and B MACWA
02202Noridian Healthcare Solutions, LLCA and B MACID
02102Noridian Healthcare Solutions, LLCA and B MACAK
02402Noridian Healthcare Solutions, LLCA and B MACWA
02302Noridian Healthcare Solutions, LLCA and B MACOR
01111Noridian Healthcare Solutions, LLCA and B MACCA
01211Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01311Noridian Healthcare Solutions, LLCA and B MACNV
01911Noridian Healthcare Solutions, LLCA and B MACAS CA CNMI GU HI NV
01112Noridian Healthcare Solutions, LLCA and B MACCA
01182Noridian Healthcare Solutions, LLCA and B MACCA
01212Noridian Healthcare Solutions, LLCA and B MACAS CNMI GU HI
01312Noridian Healthcare Solutions, LLCA and B MACNV

Billing and coding article A59032: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59032 (Billing and Coding: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59032: Billing and Coding: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia (Billing and Coding, effective 2026-01-22)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
3
Procedure codes listed
2
Full article
cms.gov record

Procedure codes: 0114U, 81479.

Coverage indications, limitations and medical necessity

Current molecular diagnostic tests that identify individuals with upper gastrointestinal metaplasia, dysplasia, and neoplasia are non-covered by this contractor.

We expect these types of tests to meet the following criteria:

• The beneficiary is being actively managed for chronic gastroesophageal reflex disease (GERD) and/or non-dysplastic Barrett’s esophagus (NDBE); and

• They also have at least three additional risk factors for Barrett’s esophagus (BE) as described in nationally recognized guidelines.

• The beneficiary has not been previously diagnosed with dysplasia or esophageal carcinoma; and

• The beneficiary is tested no more than recommended by established national or society guidelines; and

• The test identifies patients with dysplastic disease that may benefit from endoscopic treatment or surveillance, or patients with non-dysplastic disease who may benefit from surveillance; and

• The test results will be used in determining treatment or management of the beneficiary.

• The beneficiary is within the population for which the test was developed and validated. The laboratory providing the test is responsible for clearly indicating to treating clinicians the population and indication for test use.

• The test demonstrates analytical validity (AV) including an analytical and clinical validation for any given measured analytes and has demonstrated equivalence or superiority for sensitivity or specificity of detecting dysplasia to other already accepted methods for the same intended use measuring the same or comparable analytes.

• Clinical validity (CV) of any analyte measured must be demonstrated in the published peer-reviewed literature, establishing a clear and significant biological/molecular basis for stratifying patients and subsequently selecting (either positively or negatively) their clinical management decision within a clearly defined population.

• The test successfully completes a Technical Assessment that will ensure that criteria set in this policy are met to establish the test as Reasonable and Necessary.

Summary of evidence (opening)

Esophageal adenocarcinoma (EAC) has become one of the most rapidly increasing cancers in Western countries. 1-3 Although the 5-year survival rate for EAC has improved from 5% in the 1970s to nearly 20%, it is still among one of the lowest survival rates for all cancers in the United States. 3,4 Prognosis is strongly related to stage at diagnosis, with the 5-year survival rate dropping to less than 3% in patients with a late stage presentation with 40% of patients also having distal metastases. 5 , 6 As such, there is a need to improve the ability to detect and prevent EAC at an earlier stage with options of curative therapy.

Virtually all EAC arises from BE, a pre-cancerous condition of the distal esophagus where there is metaplastic replacement of the normal stratified squamous epithelium by an intestinal-type columnar epithelium with dysplasia. 7 Individuals with BE have an over 10-fold increased risk of developing EAC as compared to those without BE. 8 The prevalence of BE is estimated to be 1.6% in the general population, and higher in patients with GERD. 9-11 Additional risk factors for BE include: male sex, age >50, Caucasian race, smoking history, central obesity, and family history of BE or EAC. 7,12 Importantly, the risk of BE increases additively when there is GERD plus the presence of any additional risk factor. 13

Progression of BE to EAC often follows a prolonged course through multiple stages of dysplasia encompassing NDBE, BE with low-grade dysplasia (LGD), high grade dysplasia (HGD), intramucosal carcinoma, and finally EAC. The risk of progression of patients with NDBE to EAC is estimated to be between 0.1% and 0.6%. 8,14-17 However, once LGD develops, the risk of cancer progression increases with reported ranges between 0.6-13.4%. 14,15,18 A systematic review of over twenty studies encompassing 2700 patients by Singh et al, 19 concluded an annual progression rate from BE-LGD to EAC of 0.54% (1 in 185 patients) annually, albeit with variability across the various studies.

The concept of cellular progression has led to the hypothesis that early surveillance followed by intervention will lead to a decreased incidence of EAC. 20,21 Studies have shown that patients diagnosed through surveillance programs have earlier stage tumors and better survival than those who present with cancer. 22,23 However, guidelines from major gastroenterology societies on early endoscopic surveillance vary. 7,24-26 For example, the American Society for Gastrointestinal Endoscopy (ASGE), only conditionally recommends surveillance endoscopy in patients with NDBE based on very low quality of evidence when compared to no surveillance. 25 In addition, the ASGE states that if endoscopy for the identification of BE is performed, it should only be in at-risk patients such as those with a family history (high risk) or those with GERD plus at least one other risk factor (moderate risk). The American College of Gastroenterology (ACG) recommends assessing men with chronic (>5 years), and/or weekly or more symptoms of GERD, and two or more risk factors for BE or EAC through a single screening endoscopy and that for patients without dysplasia, endoscopic surveillance should take place at intervals of 3-5 years. 7

The contractor cites 49 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-05-28
Current revision effective
2026-01-22
Last reviewed by the contractor
2025-03-03
MCD version
8

Other related documents: A59353 (Response to Comments), A59354 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Noridian Healthcare Solutions, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39262 cover?

• The test demonstrates analytical validity (AV) including an analytical and clinical validation for any given measured analytes and has demonstrated equivalence or superiority for sensitivity or specificity of detecting dysplasia to other already accepted methods for the same intended use measuring the same or comparable analytes. The full 292-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39262 apply to?

Noridian Healthcare Solutions, LLC applies it to Medicare claims in 13 states plus 3 territories: AK, AS, AZ, CA, GU, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39262?

The current export links no billing and coding article with a diagnosis list to LCD L39262, so Noridian Healthcare Solutions, LLC decides coverage on the 292-word policy text and the documentation in the record rather than by an automated diagnosis edit.

How do I appeal a denial under LCD L39262?

A denial under LCD L39262 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications, then file a redetermination with Noridian Healthcare Solutions, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.